ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01XG01 | G | Bortezomib - 3.5mg | 10328 | 138619/1 | ALVOCADE | 3.5mg | 1 | Injectable powder for solution | IV/SC | Lebiran SARL | Nano Fanavaran Darouei Alvand Co (Nano Alvand) | Iran | 14,452,918 L.L | 10.71 | E1 | Nano Fanavaran Darouei Alvand Co (Nano Alvand) | Iran | 2/5/2024 | 0 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01XG01 | B | Bortezomib - 3.5mg | 9498 | 76118/1 | VELCADE | 3.5mg | 1 | Injectable lyophilised powder for solution | IV/SC | Mersaco | BSP Pharmaceuticals SpA | Italy | 35,212,136 L.L | 10.71 | E1 | Janssen Cilag International NV | Belgium | 2/5/2024 | 0 |
L01XG01 | G | Bortezomib - 3.5mg | 9386 | 186162/13 | BORCADE | 3.5mg | 1 | Injectable lyophilised powder | IV/SC | Benta Trading Co s.a.l. | Hetero Labs Limited, India for Benta SAL | Lebanon | 21,602,799 L.L | 19.35 | D | 2/5/2024 | 0 | ||
L01XG01 | G | Bortezomib - 3.5mg | 10687 | 189319/1 | BORCADE | 3.5mg | 1 | Injectable lyophilised powder | IV/SC | Benta Trading Co s.a.l. | Manufactured by MSN Laboratories Private Ltd, India for Benta SAL | Lebanon | 21,602,799 L.L | 19.35 | D | 2/5/2024 | 0 | ||
L01XG01 | G | Bortezomib - 3.5mg | 9477 | 146117/1 | BORTEZOMIB ACCORD | 3.5mg | 1 | Injectable powder for solution | IV/SC | Mediterranean Pharmaceutical Company | Accord Healthcare Limited | UK | 13,007,658 L.L | 21.26 | C | Accord Healthcare Limited | UK | 2/5/2024 | 0 |
L01XG01 | G | Bortezomib - 3.5mg | 11619 | 110122/1 | BORTEZOMIB GP PHARM | 3.5mg | 1 | Injectable powder for solution | IV/SC | Mediterranean Pharmaceutical Company | GP-Pharm, SA | Argentine | 13,007,658 L.L | 21.26 | C | Pharminicio SL | Spain | 2/5/2024 | 0 |
L01XG01 | G | Bortezomib - 3.5mg | 10598 | 87420/1 | BORTEZOMIB NEAPOLIS | 3.5mg | 1 | Injectable lyophilised powder for solution | IV/SC | Medis Pharm Drugstore | Neapolis Pharma | Tunisia | 35,076,021 L.L | 19.35 | D | Neapolis Pharma | Tunisia | 2/5/2024 | 0 |
L01XG01 | G | Bortezomib - 3.5mg | 11269 | 177320/1 | BORTEZOMIB SPC | 3.5mg | 1 | Injectable powder for solution | IV/SC | Advanced Healthcare Services SAL | Pharmaline SAL Licensed by Sudair Pharma Company, KSA | Lebanon | 24,002,843 L.L | 19.35 | D | 2/5/2024 | 0 | ||
L01XG01 | G | Bortezomib - 3.5mg | 10819 | 96420/1 | VELZOME | 3.5mg | 1 | Injectable powder for solution | IV/SC | Khalil Fattal & Fils S.A.L. | Salutas Pharma GmbH | Germany | 26,180,966 L.L | 19.35 | D | Hexal AG | Germany | 2/5/2024 | 0 |
L01XG01 | G | Bortezomib - 3.5mg | 10598/388 | 87420/1 | BORTEZOMIB NEAPOLIS | 3.5mg | 1 | Injectable lyophilised powder for solution | IV/SC | Medis Pharm Drugstore | Neapolis Pharma | Tunisia | L.L | 19.35 | D | Neapolis Pharma | Tunisia | 2/5/2024 |